GS vs JANX · P/E 20, rev $37.56B vs rev $10.3M
Goldman Sachs Group Inc (GS) versus Janux Therapeutics Inc (JANX) — a side-by-side from cached financials, not a winner call.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
Janux Therapeutics Inc (JANX) is a biotechnology company listed on US.
Latest reported GS revenue for 2026-06-30 was $37.56B. Net income was $12.26B. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Latest reported JANX revenue for 2026-06-30 was $10.3M. Net income was -$22.0M. JANX currently screens at market cap $1.49B.
GS currently screens at market cap $324.25B and trailing P/E 20.1. JANX currently screens at market cap $1.49B.
Not investment advice. Open the GS and JANX stock pages for the full models.
Not investment advice.